Search results
Abstract. Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [ 1 – 3 ].
22 maj 2023 · An interprofessional approach in evaluation, treatment, and care of patients with bullous systemic lupus erythematosus cannot be over-emphasized. Primary care physicians, rheumatologists, and dermatologists play a key role in early diagnosis.
Benlysta User Reviews & Ratings. Benlysta has an average rating of 7.8 out of 10 from a total of 60 reviews on Drugs.com. 67% of reviewers reported a positive experience, while 9% reported a negative experience.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus ery-thematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
8 lis 2023 · Bullous SLE is rare blistering disorder characterized by subepidermal blisters. We, hereby, present a case of bullous SLE in a 24-year-old female who responded well to systemic glucocorticoids, mycophenolate mofetil, and dapsone.
7 paź 2021 · Pharmacologic Therapy. Dapsone is the initial treatment of choice for bullous systemic lupus erythematosus. [2, 34] The response is usually dramatic, with cessation of new blister formation...
